Copyright Reports & Markets. All rights reserved.

Global Drugs for Vulvovaginal Candidiasis Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Market Overview

    • 1.1 Drugs for Vulvovaginal Candidiasis Introduction
    • 1.2 Market Analysis by Type
      • 1.2.1 Cream
      • 1.2.2 Pessary
      • 1.2.3 Other
    • 1.3 Market Analysis by Applications
      • 1.3.1 Hospital & Clinic
      • 1.3.2 Pharmacy
    • 1.4 Market Analysis by Regions
      • 1.4.1 North America (United States, Canada and Mexico)
        • 1.4.1.1 United States Market States and Outlook (2014-2024)
        • 1.4.1.2 Canada Market States and Outlook (2014-2024)
        • 1.4.1.3 Mexico Market States and Outlook (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy)
        • 1.4.2.1 Germany Market States and Outlook (2014-2024)
        • 1.4.2.2 France Market States and Outlook (2014-2024)
        • 1.4.2.3 UK Market States and Outlook (2014-2024)
        • 1.4.2.4 Russia Market States and Outlook (2014-2024)
        • 1.4.2.5 Italy Market States and Outlook (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
        • 1.4.3.1 China Market States and Outlook (2014-2024)
        • 1.4.3.2 Japan Market States and Outlook (2014-2024)
        • 1.4.3.3 Korea Market States and Outlook (2014-2024)
        • 1.4.3.4 India Market States and Outlook (2014-2024)
        • 1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
      • 1.4.4 South America, Middle East and Africa
        • 1.4.4.1 Brazil Market States and Outlook (2014-2024)
        • 1.4.4.2 Egypt Market States and Outlook (2014-2024)
        • 1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
        • 1.4.4.4 South Africa Market States and Outlook (2014-2024)
        • 1.4.4.5 Turkey Market States and Outlook (2014-2024)
    • 1.5 Market Dynamics
      • 1.5.1 Market Opportunities
      • 1.5.2 Market Risk
      • 1.5.3 Market Driving Force

    2 Manufacturers Profiles

    • 2.1 Bayer
      • 2.1.1 Business Overview
      • 2.1.2 Drugs for Vulvovaginal Candidiasis Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 Perrigo
      • 2.2.1 Business Overview
      • 2.2.2 Drugs for Vulvovaginal Candidiasis Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 J & J
      • 2.3.1 Business Overview
      • 2.3.2 Drugs for Vulvovaginal Candidiasis Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 Pfizer
      • 2.4.1 Business Overview
      • 2.4.2 Drugs for Vulvovaginal Candidiasis Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 Bristol-Myers Squibb
      • 2.5.1 Business Overview
      • 2.5.2 Drugs for Vulvovaginal Candidiasis Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 Effik
      • 2.6.1 Business Overview
      • 2.6.2 Drugs for Vulvovaginal Candidiasis Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 Teva
      • 2.7.1 Business Overview
      • 2.7.2 Drugs for Vulvovaginal Candidiasis Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 Sanofi
      • 2.8.1 Business Overview
      • 2.8.2 Drugs for Vulvovaginal Candidiasis Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 Cisen Pharmaceutical
      • 2.9.1 Business Overview
      • 2.9.2 Drugs for Vulvovaginal Candidiasis Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.10 Kingyork Group
      • 2.10.1 Business Overview
      • 2.10.2 Drugs for Vulvovaginal Candidiasis Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)

    • 3.1 Global Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2017-2018)
    • 3.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer (2017-2018)
    • 3.3 Market Concentration Rate
      • 3.3.1 Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2018
      • 3.3.2 Top 6 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2018
    • 3.4 Market Competition Trend

    4 Global Drugs for Vulvovaginal Candidiasis Market Analysis by Regions

    • 4.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Regions
      • 4.1.1 Global Drugs for Vulvovaginal Candidiasis Sales and Market Share by Regions (2014-2019)
      • 4.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Regions (2014-2019)
    • 4.2 North America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 4.3 Europe Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 4.5 South America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)

    5 North America Drugs for Vulvovaginal Candidiasis by Country

    • 5.1 North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Country
      • 5.1.1 North America Drugs for Vulvovaginal Candidiasis Sales and Market Share by Country (2014-2019)
      • 5.1.2 North America Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Country (2014-2019)
    • 5.2 United States Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 5.3 Canada Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 5.4 Mexico Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)

    6 Europe Drugs for Vulvovaginal Candidiasis by Country

    • 6.1 Europe Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Country
      • 6.1.1 Europe Drugs for Vulvovaginal Candidiasis Sales and Market Share by Country (2014-2019)
      • 6.1.2 Europe Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Country (2014-2019)
    • 6.2 Germany Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 6.3 UK Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 6.4 France Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 6.5 Russia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 6.6 Italy Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)

    7 Asia-Pacific Drugs for Vulvovaginal Candidiasis by Country

    • 7.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Country
      • 7.1.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Market Share by Country (2014-2019)
      • 7.1.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Country (2014-2019)
    • 7.2 China Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 7.3 Japan Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 7.4 Korea Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 7.5 India Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)

    8 South America Drugs for Vulvovaginal Candidiasis by Country

    • 8.1 South America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Country
      • 8.1.1 South America Drugs for Vulvovaginal Candidiasis Sales and Market Share by Country (2014-2019)
      • 8.1.2 South America Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Country (2014-2019)
    • 8.2 Brazil Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 8.3 Argentina Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 8.4 Colombia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)

    9 Middle East and Africa Drugs for Vulvovaginal Candidiasis by Countries

    • 9.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Country
      • 9.1.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Market Share by Country (2014-2019)
      • 9.1.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Country (2014-2019)
    • 9.2 Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 9.3 Turkey Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 9.4 Egypt Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 9.5 Nigeria Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)
    • 9.6 South Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2014-2019)

    10 Global Drugs for Vulvovaginal Candidiasis Market Segment by Type

    • 10.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2014-2019)
      • 10.1.1 Global Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type (2014-2019)
      • 10.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Type (2014-2019)
    • 10.2 Cream Sales Growth and Price
      • 10.2.1 Global Cream Sales Growth (2014-2019)
      • 10.2.2 Global Cream Price (2014-2019)
    • 10.3 Pessary Sales Growth and Price
      • 10.3.1 Global Pessary Sales Growth (2014-2019)
      • 10.3.2 Global Pessary Price (2014-2019)
    • 10.4 Other Sales Growth and Price
      • 10.4.1 Global Other Sales Growth (2014-2019)
      • 10.4.2 Global Other Price (2014-2019)

    11 Global Drugs for Vulvovaginal Candidiasis Market Segment by Application

    • 11.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2014-2019)
    • 11.2 Hospital & Clinic Sales Growth (2014-2019)
    • 11.3 Pharmacy Sales Growth (2014-2019)

    12 Drugs for Vulvovaginal Candidiasis Market Forecast (2019-2024)

    • 12.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2019-2024)
    • 12.2 Drugs for Vulvovaginal Candidiasis Market Forecast by Regions (2019-2024)
      • 12.2.1 North America Drugs for Vulvovaginal Candidiasis Market Forecast (2019-2024)
      • 12.2.2 Europe Drugs for Vulvovaginal Candidiasis Market Forecast (2019-2024)
      • 12.2.3 Asia-Pacific Drugs for Vulvovaginal Candidiasis Market Forecast (2019-2024)
      • 12.2.4 South America Drugs for Vulvovaginal Candidiasis Market Forecast (2019-2024)
      • 12.2.5 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Forecast (2019-2024)
    • 12.3 Drugs for Vulvovaginal Candidiasis Market Forecast by Type (2019-2024)
      • 12.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2019-2024)
      • 12.3.2 Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Type (2019-2024)
    • 12.4 Drugs for Vulvovaginal Candidiasis Market Forecast by Application (2019-2024)
      • 12.4.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2019-2024)
      • 12.4.2 Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Application (2019-2024)

    13 Sales Channel, Distributors, Traders and Dealers

    • 13.1 Sales Channel
      • 13.1.1 Direct Marketing
      • 13.1.2 Indirect Marketing
      • 13.1.3 Marketing Channel Future Trend
    • 13.2 Distributors, Traders and Dealers

    14 Research Findings and Conclusion

      15 Appendix

      • 15.1 Methodology

      The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

      Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.

      Scope of the Report:
      The classification of Drugs for Vulvovaginal Candidiasis includes Cream, Pessary and other. The proportion of Cream in 2017 is about 47.2%, and the proportion of Pessary in 2017 is about 34.1%.
      The drugs for Vulvovaginal Candidiasis are Miconazole, Clotrimazole, Fluconazole, Econazole and Other, market share of Fluconazole is about 24.5% in 2017.
      Drugs for Vulvovaginal Candidiasis is application in Hospital & Clinic and Pharmacy. The most of Drugs for Vulvovaginal Candidiasis is used in Pharmacy, and the market share in 2016 is about 59%.
      The worldwide market for Drugs for Vulvovaginal Candidiasis is expected to grow at a CAGR of roughly 2.1% over the next five years, will reach 870 million US$ in 2024, from 770 million US$ in 2019, according to a new GIR (Global Info Research) study.
      This report focuses on the Drugs for Vulvovaginal Candidiasis in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

      Market Segment by Manufacturers, this report covers
      Bayer
      Perrigo
      J & J
      Pfizer
      Bristol-Myers Squibb
      Effik
      Teva
      Sanofi
      Cisen Pharmaceutical
      Kingyork Group

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia etc.)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      Cream
      Pessary
      Other

      Market Segment by Applications, can be divided into
      Hospital & Clinic
      Pharmacy

      The content of the study subjects, includes a total of 15 chapters:
      Chapter 1, to describe Drugs for Vulvovaginal Candidiasis product scope, market overview, market opportunities, market driving force and market risks.
      Chapter 2, to profile the top manufacturers of Drugs for Vulvovaginal Candidiasis, with price, sales, revenue and global market share of Drugs for Vulvovaginal Candidiasis in 2017 and 2018.
      Chapter 3, the Drugs for Vulvovaginal Candidiasis competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
      Chapter 4, the Drugs for Vulvovaginal Candidiasis breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
      Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
      Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
      Chapter 12, Drugs for Vulvovaginal Candidiasis market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
      Chapter 13, 14 and 15, to describe Drugs for Vulvovaginal Candidiasis sales channel, distributors, customers, research findings and conclusion, appendix and data source.

      Buy now